RU2080860C1 - Лекарственное средство для лечения шизофрении и способ его получения - Google Patents

Лекарственное средство для лечения шизофрении и способ его получения Download PDF

Info

Publication number
RU2080860C1
RU2080860C1 SU915052142A SU5052142A RU2080860C1 RU 2080860 C1 RU2080860 C1 RU 2080860C1 SU 915052142 A SU915052142 A SU 915052142A SU 5052142 A SU5052142 A SU 5052142A RU 2080860 C1 RU2080860 C1 RU 2080860C1
Authority
RU
Russia
Prior art keywords
clozapine
ascorbic acid
radical
acceptor
treatment
Prior art date
Application number
SU915052142A
Other languages
English (en)
Russian (ru)
Inventor
Фишер Фолькер
Пол Мейсон Рональд
Original Assignee
Сандос Лтд.
Тэ Юнайтед Стейтс оф Америка Репрезентед бай тэ Секретари Юнайтед Стейтс Дипартмент оф Хэлф энд Хьюман Сервис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сандос Лтд., Тэ Юнайтед Стейтс оф Америка Репрезентед бай тэ Секретари Юнайтед Стейтс Дипартмент оф Хэлф энд Хьюман Сервис filed Critical Сандос Лтд.
Application granted granted Critical
Publication of RU2080860C1 publication Critical patent/RU2080860C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SU915052142A 1990-08-20 1991-08-14 Лекарственное средство для лечения шизофрении и способ его получения RU2080860C1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56968990A 1990-08-20 1990-08-20
US07/569.689 1990-08-20
US71713691A 1991-06-18 1991-06-18
US07/717.136 1991-06-18
PCT/EP1991/001542 WO1992003138A1 (en) 1990-08-20 1991-08-14 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
RU2080860C1 true RU2080860C1 (ru) 1997-06-10

Family

ID=27075116

Family Applications (1)

Application Number Title Priority Date Filing Date
SU915052142A RU2080860C1 (ru) 1990-08-20 1991-08-14 Лекарственное средство для лечения шизофрении и способ его получения

Country Status (30)

Country Link
US (2) US5312819A (enExample)
JP (1) JPH0813745B2 (enExample)
KR (1) KR100189349B1 (enExample)
AT (1) AT400522B (enExample)
AU (1) AU649269B2 (enExample)
BE (1) BE1006878A5 (enExample)
CA (1) CA2065421A1 (enExample)
CH (1) CH684162A5 (enExample)
CZ (1) CZ281843B6 (enExample)
DE (1) DE4191979T (enExample)
DK (1) DK51292D0 (enExample)
ES (1) ES2078838B1 (enExample)
FI (1) FI913888A7 (enExample)
FR (1) FR2665835B1 (enExample)
GB (1) GB2254252B (enExample)
GR (1) GR1002188B (enExample)
HU (1) HUT60137A (enExample)
IE (1) IE66121B1 (enExample)
IL (1) IL99224A (enExample)
IT (1) IT1251226B (enExample)
LU (1) LU88099A1 (enExample)
MX (1) MX9100742A (enExample)
MY (1) MY107976A (enExample)
NL (1) NL9120006A (enExample)
NZ (1) NZ239464A (enExample)
PT (1) PT98707B (enExample)
RU (1) RU2080860C1 (enExample)
SE (1) SE9201189D0 (enExample)
SK (1) SK279225B6 (enExample)
WO (1) WO1992003138A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2441651C1 (ru) * 2010-12-23 2012-02-10 Маргарита Алексеевна Морозова Способ получения фармацевтической композиции клозапина в виде таблеток и фармацевтическая композиция
RU2610169C2 (ru) * 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008801A1 (en) * 1991-10-31 1993-05-13 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Prevention of drug-induced agranulocytosis with free radical scavengers
US5538965A (en) * 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
JP2001520978A (ja) * 1997-10-27 2001-11-06 コーテックス ファーマシューティカルズ， インコーポレイテッド アンパカインおよび神経遮断薬を用いる精神分裂病の処置
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
JP2003026567A (ja) * 2001-05-10 2003-01-29 Kanegafuchi Chem Ind Co Ltd 補酵素ｑを有効成分とする粘膜投与用組成物
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP2299983A4 (en) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI50242C (fi) * 1969-07-18 1976-01-12 Thomae Gmbh Dr K Menetelmä valmistaa farmakologisesti aktiivisia uusia diallyyliaminoal kanoyylidibenso- tai pyridobenso-diatsepiineja ja niiden happoadditios uoloja.
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US4028467A (en) * 1975-01-07 1977-06-07 Berger Frank M Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
DE3069716D1 (en) * 1979-10-01 1985-01-10 Sandoz Ag Dibenzazepine derivatives, their production and pharmaceutical compositions containing them
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
US4996199A (en) * 1988-04-08 1991-02-26 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
JP2903318B2 (ja) * 1989-04-04 1999-06-07 日研フード株式会社 抗酸化的ストレス物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, ч.1, с.67, 1986. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2441651C1 (ru) * 2010-12-23 2012-02-10 Маргарита Алексеевна Морозова Способ получения фармацевтической композиции клозапина в виде таблеток и фармацевтическая композиция
RU2610169C2 (ru) * 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ

Also Published As

Publication number Publication date
NL9120006A (nl) 1992-08-03
NZ239464A (en) 1993-10-26
KR100189349B1 (en) 1999-06-01
US5312819A (en) 1994-05-17
FR2665835B1 (fr) 1995-06-23
IE66121B1 (en) 1995-12-13
ITMI912261A0 (it) 1991-08-20
IL99224A (en) 1996-01-31
GB9206101D0 (en) 1992-06-24
CA2065421A1 (en) 1992-02-21
JPH05503296A (ja) 1993-06-03
SE9201189L (sv) 1992-04-14
MX9100742A (es) 1992-04-01
FI913888L (fi) 1992-02-21
ITMI912261A1 (it) 1993-02-20
MY107976A (en) 1996-07-15
HU9201090D0 (en) 1992-06-29
DK51292A (da) 1992-04-15
IL99224A0 (en) 1992-07-15
SE9201189D0 (sv) 1992-04-14
WO1992003138A1 (en) 1992-03-05
SK279225B6 (sk) 1998-08-05
FI913888A7 (fi) 1992-02-21
ES2078838B1 (es) 1997-02-01
GB2254252B (en) 1994-06-01
GR1002188B (en) 1996-03-13
DE4191979T (enExample) 1992-10-08
KR920702225A (ko) 1992-09-03
ATA900491A (de) 1995-06-15
DK51292D0 (da) 1992-04-15
HUT60137A (en) 1992-08-28
AT400522B (de) 1996-01-25
JPH0813745B2 (ja) 1996-02-14
US5563134A (en) 1996-10-08
AU649269B2 (en) 1994-05-19
FR2665835A1 (fr) 1992-02-21
LU88099A1 (de) 1992-11-16
GB2254252A (en) 1992-10-07
PT98707B (pt) 1999-01-29
FI913888A0 (fi) 1991-08-16
IE912934A1 (en) 1992-02-26
GR910100361A (el) 1992-08-31
IT1251226B (it) 1995-05-05
CZ281843B6 (cs) 1997-02-12
AU8396391A (en) 1992-03-17
CH684162A5 (de) 1994-07-29
CS55092A3 (en) 1992-08-12
ES2078838A1 (es) 1995-12-16
BE1006878A5 (fr) 1995-01-17
PT98707A (pt) 1992-07-31

Similar Documents

Publication Publication Date Title
Dahl‐Puustinen et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings
RU2080860C1 (ru) Лекарственное средство для лечения шизофрении и способ его получения
RO120567B1 (ro) Compoziţie de substanţe biochimice, pentru scăderea lipoproteinei (a) din plasmă şi a factorilor de risc pentru afecţiuni cardiovasculare
JPH08505853A (ja) コレステロール低下剤および抗酸化剤を含んで成る組成物
US4341774A (en) Method for suppressing abnormal rise in immunological function and agent useful therefor
US6605605B2 (en) Estrogenic substances combined with cruciferous indole compounds
Potter et al. Activated charcoal: in vivo and in vitro studies of effect on gas formation
US6274621B1 (en) Ginkgolides for inhibition of membrane expression of benzodiazepine receptors
Kessel et al. Neurotoxicity related to lithium and neuroleptic combinations? A retrospective review
Ashton Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat
Archer et al. Rifampin blood and tissue levels in patients undergoing cardiac valve surgery
EP0862428B1 (en) Ginkgolides for inhibition of membrane expression
de Greet et al. Four cases of fatal doxepin poisoning
KR980008237A (ko) 오미자로부터 아실-코에이 : 콜레스테롤 아실트랜스퍼라제(acat) 활성저해제의 제조방법 및 이를 함유하는 조성물
Gruber Diazepam loading: Simplified treatment of alcohol withdrawal: Sellers EM, Naranjo CA, Harrison M, et al. Clin Pharmacol Ther 1983; 34: 822–826
WO1993008801A1 (en) Prevention of drug-induced agranulocytosis with free radical scavengers
JP2007507479A (ja) 脂質代謝を調節するための方法および手段
Mueller Acute isopropyl alcohol intoxication. Diagnosis and management: Lacouture PG, Wason S, Abrams A, Lovejoy FH Jr. Am J Med 1983; 75: 680–686
GB2047092A (en) Hypolipideamic agents containing methyl L-methionine sulfonium salts